NS 580
Alternative Names: NS-580Latest Information Update: 06 Nov 2024
Price :
$50 *
At a glance
- Originator Nippon Shinyaku
- Class Analgesics; Infertility therapies
- Mechanism of Action Prostaglandin-E synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometriosis; Pelvic pain; Prostatitis
Most Recent Events
- 18 Jan 2024 Nippon Shinyaku completes a phase I pharmacokinetics trial (In volunteers, In adults) in United Kingdom (PO) (NCT06670898)
- 08 Nov 2023 Nippon Shinyaku initiates a phase I pharmacokinetics trial (In volunteers, In adults) in United Kingdom (PO) (NCT06670898)
- 21 Aug 2023 Phase-II clinical trials in Pelvic pain in Japan (PO) (Nippon Shinyaku pipeline; August 2023)